Patents by Inventor Nicholas D. Mazarakis

Nicholas D. Mazarakis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • LENTIVIRAL VECTORS WITH TROPISM TO MOTOR NEURONS COMPRISING AN ANTIBODY THAT BINDS TO A PRE-SYNAPTIC TERMINAL RECEPTOR ON THE NEUROMUSCULAR JUNCTION AND A FUSOGENIC PROTEIN
    Publication number: 20160101174
    Abstract: The present invention relates to vectors useful in the treatment of disease through targeted delivery. In particular, the present invention relates to vectors useful in the treatment of disease associated with neuronal degeneration, such as amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA).
    Type: Application
    Filed: May 15, 2014
    Publication date: April 14, 2016
    Inventors: Nicholas D. MAZARAKIS, Ioanna ELEFTHERIADOU, Antonio TRABALZA
  • Vector system
    Patent number: 7259015
    Abstract: Provided are retroviral vector genomes and vector systems comprising the genomes. In particular, a retroviral vector genome comprising two or more NOIs, operably linked by one or more Internal Ribosome Entry Site(s); a lentiviral vector genome comprising two or more NOIs suitable for treating a neurodegenerative disorder; and a lentiviral vector genome which encodes tyrosine hydroxylase, GTP-cyclohydrolase I and, optionally, Aromatic Amino Acid Dopa Decarboxylase are provided.
    Type: Grant
    Filed: April 7, 2003
    Date of Patent: August 21, 2007
    Assignee: Oxford Biomedia (UK) Limited
    Inventors: Alan John Kingsman, Nicholas D. Mazarakis, Enca Martin-Rendon, Mimoun Azzouz, Jonathan Rohll
  • Use of a lentiviral vector in the treatment of pain
    Publication number: 20040170608
    Abstract: Provided is a method for treating and/or preventing pain, in which a vector system is administered such that an EOI is delivered to a DRG of the subject. Also provided is a method for delivering an EOI to the spinal cord using such a vector system. Further provided is a method for identifying and/or validating an EOI by delivering a test EOI to target cell; analyzing the effect of the EOI on the target cell; and selecting an EOI with therapeutic potential. An EOI identified or validated by such a method, useful in the prevention and/or treatment of pain, is thereby provided as well.
    Type: Application
    Filed: March 12, 2004
    Publication date: September 2, 2004
    Inventors: Rob Barber, Mimoun Azzouz, Nicholas D. Mazarakis, Susan Kingsman
  • Vector system
    Publication number: 20040013648
    Abstract: Provided are retroviral vector genomes and vector systems comprising the genomes. In particular, a retroviral vector genome comprising two or more NOIs, operably linked by one or more Internal Ribosome Entry Site(s); a lentiviral vector genome comprising two or more NOIs suitable for treating a neurodegenerative disorder; and a lentiviral vector genome which encodes tyrosine hydroxylase, GTP-cyclohydrolase I and, optionally, Aromatic Amino Acid Dopa Decarboxylase are provided.
    Type: Application
    Filed: April 7, 2003
    Publication date: January 22, 2004
    Inventors: Alan John Kingsman, Nicholas D. Mazarakis, Enca Martin-Rendon, Mimoun Azzouz, Jonathan Rohll